News
A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.
Tocilizumab significantly reduced 28-day mortality and length of ICU stay in patients with severe COVID-19 pneumonia and low S-spike nAb titers.
On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...
Vaccination against COVID-19 is crucial for individuals with multiple sclerosis (MS), ensuring safety and effectiveness despite immunosuppressive therapies.
New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem ...
Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent higher for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results